Skip Navigation



IJE Advance Access published online on January 9, 2008
International Journal of Epidemiology, doi:10.1093/ije/dym264
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrowOA All Versions of this Article:
37/1/53    most recent
dym264v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Haas, J.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Haas, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008; all rights reserved.
The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access version of this article for non-commercial purposes provided that: the original authorship is properly and fully attributed; the Journal and Oxford University Press are attributed as the original place of publication with the correct citation details given; if an article is subsequently reproduced or disseminated not in its entirety but only in part or as a derivative work this must be clearly indicated. For commercial re-use, please contact journals.permissions@oxfordjournals.org Published by Oxford University Press on behalf of the International Epidemiological Association

Commentary: Epidemiology and the pharmaceutical industry: an inside perspective

Joanna Haas*

* Pharmacovigilance, Genzyme Corporation, For the Pharmaceutical Research and Manufacturers of America (PhRMA) Pharmocovigilance and Epidemiology Group, 675 W Kendall Street, Cambridge MA 02142, USA.

E-mail: joanna.haas@genzyme.com

Accepted 25 July 2007

The first 10% of the full text of this article appears below.

Neil Pearce's impassioned comments on ‘Corporate Influences on Epidemiology’1 are designed to raise awareness of industry activities that he believes ‘are major threats to the integrity of the field, and its survival as a scientific discipline’. He argues that ‘for every independent epidemiologist studying the side effects of medicines there are several other epidemiologists hired by industry to attack the research and debunk it as "junk science"’. While we recognize his depth of feeling, passion may nurture bias of its own. The relationship between science and industry is complex, and the role of epidemiologists in the pharmaceutical industry is not limited to debunking ‘junk science’. Balanced evaluation and discussion are necessary to provide accurate safety information to physicians and patients. Unfortunately, such temperate interchanges rarely make headlines and seldom sell books.2

According to Dr Pearce, the tobacco industry, the pharmaceutical industry and all the . . . [Full Text of this Article]


   The role of epidemiology in drug development
 

   Pharmaceutical industry standards on study conduct and quality
 

   Challenges in the interpretation of pharmacoepidemiologic research
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Int J EpidemiolHome page
G. Davey Smith
Big business, big science?
Int. J. Epidemiol., February 1, 2008; 37(1): 1 - 3.
[Full Text] [PDF]

Home page
 Int J EpidemiolHome page
N. Pearce
Response: The distribution and determinants of epidemiologic research
Int. J. Epidemiol., February 1, 2008; 37(1): 65 - 68.
[Full Text] [PDF]